Prevention Is the Best Medicine — Stopping Disease Before It Starts

The Case for Prevention-First Healthcare

In a world where healthcare systems face mounting pressure from ageing populations, chronic disease epidemics, and the ever-present threat of emerging infections, the argument for investing in prevention has never been more compelling. Treating disease after it occurs is essential, but it is also reactive, costly, and often too late to prevent lasting harm. Prevention — through vaccination, early screening, lifestyle interventions, and public health measures — offers a fundamentally different approach: one that keeps people healthy, reduces suffering, and delivers enormous economic value to societies.

At GSK, the belief that prevention is the best medicine is not just a slogan — it is a strategic imperative that shapes how the company invests in research, develops products, and engages with health systems around the world. With one of the broadest vaccines portfolios in the industry and a growing pipeline of preventive therapies, GSK is working to ensure that more people can benefit from the power of prevention.

The Global Burden of Preventable Disease

The scale of preventable disease is staggering. According to the World Health Organisation, vaccines alone prevent an estimated 3.5 to 5 million deaths every year from diseases including influenza, measles, tetanus, and pertussis. Yet millions more deaths occur annually from diseases for which vaccines exist but are underutilised, or for which effective vaccines have not yet been developed.

Consider the following:

• Pneumococcal disease kills nearly 300,000 children under five each year, primarily in low- and middle-income countries where vaccine coverage remains insufficient.
• RSV is responsible for approximately 100,000 deaths annually in children under five and poses a growing threat to older adults worldwide.
• Shingles affects one in three people during their lifetime, causing debilitating pain and long-term neurological complications, yet vaccination rates among eligible adults remain well below optimal levels.
• Meningococcal disease, while relatively rare, can be devastating — striking quickly, killing within hours, and leaving survivors with life-altering disabilities.

GSK’s Vaccines: A Portfolio Built on Prevention

GSK’s vaccines portfolio is one of the most comprehensive in the biopharmaceutical industry, spanning more than 20 diseases and reaching hundreds of millions of people each year. Key areas of focus include:

• RSV prevention: GSK’s RSV vaccine represents a breakthrough in protecting older adults against a virus that has long lacked effective prevention options.
• Shingles prevention: GSK’s adjuvanted recombinant vaccine has set a new standard in shingles prevention, demonstrating over 90% efficacy across age groups and in immunocompromised populations.
• Meningitis prevention: GSK offers vaccines covering multiple meningococcal serogroups, protecting infants, adolescents, and adults against this unpredictable disease.
• Pandemic preparedness: GSK’s adjuvant technology platform was a critical enabler during the COVID-19 pandemic, and the company continues to invest in pandemic readiness infrastructure.

Beyond Vaccines: A Holistic Prevention Strategy

While vaccines are the most visible expression of GSK’s prevention-first philosophy, the company’s approach extends beyond immunisation. GSK invests in research to understand the earliest stages of disease — the molecular and cellular events that precede clinical symptoms — with the aim of developing interventions that can halt disease progression before it causes harm.

In oncology, for example, research into early detection biomarkers and risk-stratification tools could enable clinicians to identify patients at highest risk of developing cancer and intervene with targeted preventive therapies. In respiratory medicine, GSK is exploring approaches that address the underlying inflammatory processes that drive conditions like asthma and COPD, rather than simply managing symptoms.

Health Equity and Global Access

Prevention only works if it reaches everyone. GSK’s global health strategy is built on the principle that life-saving vaccines and medicines should be accessible to all, regardless of geography or income. Ranked 2nd in the Access to Medicine Index, GSK works with partners including the WHO, Gavi, UNICEF, and the Bill & Melinda Gates Foundation to ensure that innovative vaccines are available in the countries and communities where they are needed most.

This commitment extends to pricing, supply chain investment, technology transfer, and capacity building in low- and middle-income countries. By strengthening local manufacturing capabilities and supporting immunisation programme delivery, GSK is helping to build resilient health systems that can sustain prevention efforts for the long term.

A Healthier Future Starts with Prevention

The evidence is clear: prevention saves lives, reduces suffering, and delivers extraordinary value to individuals, communities, and economies. As GSK continues to advance its vaccines portfolio and pipeline, the company remains committed to a vision of healthcare where prevention comes first — where the goal is not just to treat disease, but to stop it before it starts. Together, we can get ahead of disease and build a healthier future for all.